BioNTech Puts $1 Billion Buyback and Cost Cuts at Center of Oncology Transition

BioNTech is betting on a combination of share buybacks, factory closures, and a rapidly expanding oncology pipeline to convince investors its post-pandemic future is taking shape. The German biotech laid out its most detailed late-stage clinical roadmap yet at this year’s ASCO meeting, even as cost discipline moves to the forefront.

The Mainz-based company ended the first quarter with €16.8 billion in cash, equivalents and securities — a war chest that allows management to pursue both internal development and a proposed $1 billion share repurchase over the next twelve months. At the same time, BioNTech plans to exit production sites in Idar-Oberstein, Marburg and Singapore, along with several former CureVac facilities. The restructuring could affect up to 1,860 jobs and aims to deliver €500 million in annual recurring savings by 2029.

Market reaction has been cautious. The stock closed at €79.00 on Monday, down 4.07% on the day, and has lost 20.12% over the past twelve months. The weekly picture is slightly brighter: at €82.50, the shares gained 3.38% in the last five trading days, but the broader trend reflects skepticism about an oncology pivot that has yet to produce a commercial product.

That pivot now has two pillars. The lead candidate, trastuzumab pamirtecan (BNT323), is a HER2-directed antibody-drug conjugate that posted a 47.9% confirmed objective response rate in a 145-patient Phase 2 cohort, with a median progression-free survival of 8.1 months. In the HER2 IHC 3+ subgroup the response rate topped 70%. BioNTech and partner DualityBio aim to file a US Biologics License Application with the FDA in 2026, after further regulatory dialogue. A Phase 3 trial comparing the drug to chemotherapy in pre-treated patients with HER2-expressing recurrent endometrial carcinoma is already underway. The candidate has held Fast Track and Breakthrough Therapy designations since 2023.

Should investors sell immediately? Or is it worth buying BioNTech?

The second pillar is pumitamig, a bispecific PD-L1xVEGF-A immunomodulator being tested with Bristol Myers Squibb in previously untreated advanced non-small cell lung cancer. At ASCO, the companies presented interim data from the global Phase 2 ROSETTA-Lung-02 study with a cutoff date of April 13, 2026 and a median follow-up of nine months. Among 40 evaluable patients, the confirmed objective response rate in the non-squamous arm stood at 57.1%, while in the squamous arm it reached 68.4% (73.7% on an unconfirmed basis). The partners selected a lower 1,400mg dose for the late-stage portion of the trial, where confirmed response rates improved to 63.6% in non-squamous and 72.2% in squamous patients. This dataset marks the third global signal of consistent activity for pumitamib plus chemotherapy, following earlier data in small cell lung cancer and triple-negative breast cancer.

Beyond these two, BioNTech showcased BNT326/YL202, a HER3 ADC in Phase 1b/2 as a monotherapy and in combination with pumitamib, and BNT324/DB-1311, a B7H3-targeting agent for metastatic castration-resistant prostate cancer. By year-end the company expects to have 15 active pivotal studies, with seven late-stage oncology data readouts planned for 2026 — including the planned BLA for trastuzumab pamirtecan. Five new pivotal studies have already been initiated for pumitamib, covering triple-negative breast cancer, MSS colorectal cancer, gastric cancer and two NSCLC settings.

The progress comes against strong competitive headwinds. In the same ASCO session, Summit Therapeutics presented Phase 3 data from HARMONi-6 showing that ivonescimab improved median overall survival over tislelizumab in advanced squamous NSCLC — 27.9 months versus 23.7 months. While BioNTech’s pumitamid is earlier in development, the result underscores the high bar for bispecifics in this space.

BioNTech at a turning point? This analysis reveals what investors need to know now.

UBS upgraded BioNTech from Neutral to Buy in late May, raising its price target to $135 from $117. Analyst David Dai, speaking when the stock was at $92.25, saw roughly 47% upside and called pumitamib a credible contender for a best-in-class position in its drug class.

Financially, the transition remains expensive. BioNTech posted first-quarter revenue of $118.1 million and a net loss of $494.6 million, driven by heavy R&D investment. The balance sheet provides ample runway, but the clock is ticking for the oncology story to deliver its first US regulatory approval.

Ad

BioNTech Stock: New Analysis - 1 June

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

en | US09075V1026 | BIONTECH | boerse | 69464855 |